2026 Future Healthcare & Pharma Top 100 Summit: Forum on Global Expansion of Medical Devices and Pharmaceuticals – Collaborative Overseas Entry and Compliance-Driven Growth

China’s pharmaceutical and medical device industry stands at the forefront of globalization, making international expansion a core challenge that every company must urgently address. As domestic market growth margins slow, sustained release of healthcare demand in the global market presents new growth opportunities. Leveraging cost-effectiveness and manufacturing advantages, Chinese pharmaceuticals and medical devices are going global, yet the path to internationalization is far from simple.

From the tightening of the EU MDR to challenges such as difficulties in cross-border payments, insufficient brand trust, and localized operations, Chinese pharmaceutical and medical device companies are gradually realizing that international market expansion is not merely a sales activity, but encompassesMarket Access, Compliance, Commercialization, and Long-term Operationssystems engineering.

Against this backdrop, a question has become increasingly apparent:How Can Chinese Pharmaceutical and Medical Device Assets Achieve a Full Closed Loop from Product Export to Asset Globalization?

Centering on this issue, the 2026 Future Healthcare & Pharma Top 100 Conference will feature a special forum on international market expansion for pharmaceuticals and medical devices, bringing togetherAstraZeneca, PwC, LinkedIn, China Chamber of Commerce for Import and Export of Medicines and Health Products, Bill & Melinda Gates Foundationdistinguished guests from leading institutions, as well as numerous hands-on executives from frontline enterprises expanding overseas, focusing on the real challenges, pain points, and practical solutions for the global development of pharmaceutical and medical device companies. The event aims to build an efficient matchmaking platform connecting enterprises, service providers, capital, and overseas partners, facilitating the transition of pharmaceutical and medical device assets from “product exports” to a new stage of brand globalization and asset globalization.

Forum Core Information

Forum Name: International Market Expansion Forum for Pharmaceuticals and Medical Devices

Forum Time: May 19, 2026, 09:00-18:00

Forum Duration: 1 Day

Forum Venue: Hall 182, Platinum Hanjue Hotel, Minhang District, Shanghai

Organizer: VCBeat

Supporting Organizations:

Global Health Economics Branch of the Chinese Society for Health Economics

Shanghai Biomedical Science and Technology Industry Promotion Center

PwC China

LinkedIn China

China Chamber of Commerce for Import and Export of Medicines and Health Products

The agenda for this forum is based on the accumulated experience from China’s practice in expanding the international market for pharmaceuticals and medical devices.Cognition – Pathway – Ecosystema complete logical framework.

Morning Agenda: Focus on Cognitive Breakthroughs and Pathway Selection: Starting with insights into industry trends and policies, this approach aims to reverse the inherent short-sighted mindset of enterprises going global, establishing a philosophy of long-term cultivation and deep localization; through practical sharing on European market regulation, innovation in low-resource markets, and advanced License-out pathways, it provides key directions for corporate action.

Afternoon Agenda: Focusing on Implementation and Ecosystem Co-construction: Focusing on operational pain points such as cross-border fund risk control, brand trust building, regional market access, and industrial chain collaborative breakthroughs, we deconstruct practical, directly replicable solutions; ultimately concluding with the construction of a global capability system to promote industrial chain synergy and clustered enterprise development, enabling the globalization of pharmaceutical and medical device assets to evolve from “going it alone” to “collaborative win-win.”

The forum consistently centered on the concept of international market expansion, emphasizing symbiotic growth and shared prosperity with local markets. It addressed compliance breakthroughs in developed countries, incremental market development in low- and middle-income countries, and precise strategic layout in “Belt and Road” markets, thereby comprehensively covering the full-cycle needs of enterprises in their globalization journey.

This forum closely addresses the real pain points faced by pharmaceutical and medical device companies in their globalization journey, providing attendees with concrete solutions to help enterprises achieve comprehensive upgrades from strategy to execution.

Release the latest industry trends of Chinese medical devices going global, and interpret the growth pattern of the global market;

Analyzing the Regulatory Policies and Practical Implementation Paths of the Belt and Road Initiative to Eliminate Policy Awareness Barriers.

Detailed Analysis of Market Access Regulations, Cultural Differences, and Operational Strategies in Key Markets Including Southeast Asia (Malaysia) and Europe (Germany);

Breaking through the dilemma of “hesitation to enter” and “inability to enter” in the low- and middle-income market, tapping into an incremental market of hundreds of millions of people.

Interpretation of Hidden Rules: EU MDR Registration, Local Taxation, and Compliance Operations;

Addressing core pain points such as difficulties in repatriating overseas funds, low brand premium, and a shortage of localized talent;

Share innovative strategies for online channels and consumer healthcare, leveraging the advantages of China’s industrial supply chain.

Jointly initiated by PwC China, LinkedIn China, the Ferryman Supply Chain Management Club, and VCBeatGlobal Platform for International Collaboration on Pharmaceutical and Medical Device ProductsThe Global Medical Products Collaboration Platform (GMPC) was officially established, with VCBeat serving as the permanent secretariat to create an “integrated operating system” for Chinese pharmaceutical and medical device enterprises going global.

The GMPC 2026 Key Promotion Plan will also be released at the conference. GMPC is committed to becoming a core support platform for Chinese pharmaceutical and medical device manufacturers to efficiently expand into global markets. Rooted in China’s robust pharmaceutical and medical device supply chain, the platform connects upward with global public health procurement, mainstream commercial channels, and cross-border compliance standards, systematically addressing core pain points faced by Chinese enterprises in their internationalization journey, such as information asymmetry, high market entry barriers, and significant compliance risks. The platform integrates “Industry Research + Compliance & Risk Control + Channel Linkage + Financial EmpowermentIntegrating four core functions, it transforms fragmented overseas expansion needs into a standardized “Product Globalization Roadmap,” providing Chinese pharmaceutical and medical device companies with full lifecycle support from the laboratory to overseas end markets.

By constructing a tripartite collaborative matrix integrating manufacturers, service providers, and distributors, GMPC serves not merely as an information hub, but as a practical collaboration network that empowers Chinese enterprises to transition from “capacity export” to “standard export” and “brand export,” thereby enabling Chinese medical technology to truly benefit the global market. During its establishment, the platform received strong support from organizations such as the China Chamber of Commerce for Import and Export of Medicines and Health Products, the Global Health Economics Branch of the Chinese Society of Health Economics, and the Bill & Melinda Gates Foundation.

This forum brings together industry authorities, regional experts, frontline corporate executives, and professional service agencies to construct a comprehensive cognitive and practical framework for the internationalization of pharmaceuticals and medical devices. Centered on four key dimensions—“Trend Assessment, Market Entry, Corporate Implementation, and Capability Support”—the event offers end-to-end insights, ranging from policy analysis to actionable pathways, and from case studies to implementation solutions.

More speakers to be announced.

Focusing on macro industry trends and global regulatory changes, we interpret the latest policy directions for the internationalization of pharmaceuticals and medical devices, helping companies clarify their pathways and avoid unnecessary detours.

Wang Maochun | Vice President, China Chamber of Commerce for Import and Export of Medicines and Health Products

Zhang Hua | Deputy Director, Shanghai Biomedical Science and Technology Industry Promotion Center

Zhang Xiaohui | Deputy Director of the Department of International Cooperation, China Chamber of Commerce for Import and Export of Medicines and Health Products

Kuang Yudi | Director of the Development and Operations Center, Guangdong Research Institute for Novel Biomaterials and High-End Medical Devices

Focusing on the markets of Southeast Asia and low-resource countries, this analysis delves into market access pathways, collaboration models, and localization strategies, providing companies with actionable frameworks for regional expansion.

Bai Yujing | Senior Program Officer, Health Innovation and Collaboration, Bill & Melinda Gates Foundation

Chen Kai | Executive Director, International Business Development & Investment, AstraZeneca; Head of Ecosystem Partnerships

Zhang Runxuan | Director, Center for International Cooperation Projects, University of Malaya

Lu Zhudi | Co-founder and Chief Operating Officer of Xudongsheng

Wang Lijue | Chairman and CEO of Akang Health Group

Bringing together frontline executives from companies expanding overseas, we provide a genuine review of global market entry experiences. Focusing on key areas such as regulatory registration and market access, brand building, and commercial operations, we share replicable, practical strategies.

Shi Yonghui | Executive Director of MicroTech Medical
Zhao Chunsheng | Deputy General Manager of Aier Eye Hospital Group Co., Ltd.
Wu Ming | Vice President of Business Development, Zhejiang Tongyuan Kang Pharmaceutical Co., Ltd.
Qi Xiulan | Director of Clinical Marketing Department, Sonoscape Medical
Wang Dong | General Manager, Weijing Zhizhong (Hong Kong) Co., Ltd.
Zhang Jiutao | Partner at Weilai Capital
Xian Xuan | Dean, AI Drug Research Institute, GenSci Pharmaceutical
Wang Junsu | Deputy General Manager, Beijing Motic Medical Technology Co., Ltd.

Bringing together professional expertise in capital, finance, branding, supply chain, and international cooperation, we address core challenges such as cross-border payment collection, brand premium, and compliant operations, providing foundational support for enterprises’ global expansion.

Xu Dikun | Partner, Corporate Finance and M&A, PwC China

Cai Xiaodan | General Manager, LinkedIn China Marketing Solutions

Wang Yaomin | Chairman of the Ferryman Supply Chain Management Club

Meng Conghui | Partner, MedLinks Global

Bi Yuanfeng | Co-founder and Chief Operating Officer of VCBeat

Multiple industry leaders have confirmed their attendance, with a special mystery guest making a grand appearance to share firsthand market insights and high-value expertise. Stay tuned!

The “Top 100 Chinese Pharmaceutical Assets” initiative is dedicated to its core mission of “connecting buyers and sellers, and revitalizing pharmaceutical assets.” The International Market Expansion Forum for Pharmaceuticals and Medical Devices, as a key sub-forum of this event, serves both as a platform for exchanging corporate globalization experiences and as a matchmaking venue between capital and high-quality pharmaceutical and medical device assets.

Whether you are a pharmaceutical or medical device enterprise seeking global growth, an investment institution in search of high-quality targets, or a service partner deeply rooted in overseas markets, you will find precisely matched resources, practical and implementable solutions, and partners for long-term symbiotic growth.

May 19: We look forward to meeting you in Shanghai to explore new opportunities in the international market, address globalization challenges, and embark on a new journey in the global expansion of pharmaceutical and medical device assets!

Which market are you most focused on? What types of resources do you most hope to connect with? And what practical insights are you most eager to hear?

The International Market Expansion Forum for Pharmaceuticals and Medical Devices is now calling for submissions on “Overseas Expansion Needs and Topics” from across the industry, sincerely inviting participation from all sectors to jointly define the core agenda of this forum.

Return on Participation:

● Receive one complimentary ticket to the Pharmaceutical and Medical Device International Market Expansion Forum at the 2026 Top 100 Future Healthcare & Pharma Conference

● Contributors of high-quality topics will receive one opportunity to publish overseas supply and demand information on the VCBeat platform.

Submission Portal

Forum Registration